As part of our ongoing effort to raise awareness and promote education about #epilepsy, we explore the seizure spectrum and delve deep into the epileptic pathways. In the hope that it can be a useful resource to gain a comprehensive understanding of epilepsy and its impact on the lives of those who suffer from it. https://lnkd.in/dK_SFpEj #AngeliniPharma #EveryStepCloser #WithYouInMind
Angelini Pharma
Fabbricazione di prodotti farmaceutici
Rome, RM 132.911 follower
La nostra passione per la scienza ci guida ogni giorno nel prenderci cura della salute delle persone.
Chi siamo
In Angelini Pharma lavoriamo ogni giorno per crescere come azienda farmaceutica leader che fa la differenza nella vita dei pazienti. Dal 1919. Il nostro obiettivo è diventare uno dei principali attori europei, offrendo alle persone, ai pazienti e ai loro cari nuovi farmaci e soluzioni per ottenere risultati migliori in termini di salute e di qualità della vita. Realizziamo la nostra vision attraverso una robusta crescita della pipeline, solide collaborazioni con i migliori istituti di ricerca e preziose partnership con i nostri alleati strategici. Ci impegniamo a sviluppare con successo trattamenti distintivi per il sistema nervoso centrale, i disturbi della salute mentale e le malattie rare, mantenendo al contempo la nostra posizione di leader nel segmento della salute dei consumatori. Angelini Pharma fa parte di Angelini Industries. Social media privacy notice: https://www.angelinipharma.it/privacy/informativa-privacy-social-media/
- Sito Web
-
https://www.angelinipharma.com/
Link esterno per Angelini Pharma
- Settore
- Fabbricazione di prodotti farmaceutici
- Dimensioni dell’azienda
- 5001 - 10.000 dipendenti
- Sede principale
- Rome, RM
- Tipo
- Società privata non quotata
- Data di fondazione
- 1919
- Settori di competenza
- consumer healthcare, brain health, epilepsy e mental health
Località
Dipendenti presso Angelini Pharma
Aggiornamenti
-
In partnership with The European House-Ambrosetti, we launched Headway: A new roadmap in Brain Health, a project that aims to create a common ground for strategic reflection and dialogue on Epilepsy and Mental Health, as experienced from different European perspectives. Today 1st July, Headway is in Helsinki, welcoming local and global experts to talk about the implementation of the Intersectoral Global Action Plan on epilepsy & other neurological disorders (IGAP), with a special focus on how to break the barriers of stigma, fostering inclusion and rights for people with epilepsy. #AngeliniPharma #EveryStepCloser #WithYouInMind
-
Our Symposium “The fine line between under treatment and over treatment in uncontrolled epilepsy”, part of the European Academy of Neurology Congress 2024 in Helsinki, has just finished. Dr. Angel Aledo-Serrano has explored the topic of under treatment and the missed opportunities for reducing the seizure burden. #AngeliniPharma #EveryStepCloser #WithYouInMind #EAN2024
-
As part of the European Academy of Neurology Congress 2024 in Helsinki, our Symposium “The fine line between under treatment and over treatment in uncontrolled epilepsy” will host MD PhD Magdalena Bosak as speaker. Dr. Bosak is focusing on over treatment and the missed opportunities for reducing the treatment burden. #AngeliniPharma #EveryStepCloser #WithYouInMind #EAN2024
-
Today, we’re at the European Academy of Neurology Congress 2024 in Helsinki, Finland. Our Symposium “The fine line between under treatment and over treatment in uncontrolled epilepsy” is starting in a few hours and it will be chaired by Professor and Chief Physician Jukka Peltola. Prof. Peltola is focusing on “How to balance patient needs in the shifting epilepsy management.” #AngeliniPharma #EveryStepCloser #WithYouInMind #EAN2024
-
We're proud to announce the launch of our second crowdsourcing campaign in partnership with Wazoku. This Open Innovation Challenge aims to identify innovative Drug Delivery Systems (DDS) and Treatments Approaches to significantly improve the lives of people with epilepsy, especially elderly and pediatric patients. With 50 million people worldwide affected by epilepsy, non-adherence to anti-seizure medication among adult patients ranges from 29 to 39%, and is even lower in elderly and pediatric populations. Identifying new options to increase adherence is vital to the epilepsy community, and research is key. Researchers, scientists, and PhD students: we need your help! If you have novel approaches to using available anti-seizure medications for patients with epilepsy, join the challenge and contribute. The research journey never ends! The challenge closes on August 26. Good luck! To know more: https://lnkd.in/dJvgkyjr #AngeliniPharma #EveryStepCloser #WithYouInMind
Open Innovation Challenge
-
We’re proud to announce that in a few days we will be joining the European Academy of Neurology Congress 2024 in Helsinki, Finland, to champion neurological excellence and epilepsy care. On Sunday 30th June, as Angelini Pharma, we will hold a Symposium entitled: “The fine line between under treatment and over treatment in uncontrolled epilepsy”. Together with Professor and Chief Physician Jukka Peltola, MD PhD Angel Aledo-Serrano and MD PhD Magdalena Bosak, we will explore new perspectives in epilepsy treatment. To know more: https://lnkd.in/dmnEvp8f #AngeliniPharma #EveryStepCloser #WithYouInMind #EAN2024
-
Yesterday, we held a Symposium dedicated to #HeatTherapy in sports, as part of the GOTS Congress in Nuremberg. With Prof. Dr. Jürgen Freiwald we explored the different benefits that we can expect from heat therapy for athletes. #AngeliniPharma #EveryStepCloser
-
Later today, we will hold a special Symposium dedicated to #HeatTherapy in sports, as part of the GOTS Congress in Nuremberg. In particular, with Dr. Thilo Hotfiel we will talk about on-field management and the different roles of cold and heat therapy. #AngeliniPharma #EveryStepCloser
-
On June 20, we will participate in the GOTS Congress in Nuremberg, holding a special Symposium dedicated to #HeatTherapy in sports. Musculoskeletal pain is indeed often diagnosed on several body parts of athletes, with the neck and back being the most frequent sites of pain (31%), followed by the knee (25%), hip (20%) and shoulders (15%). Prof. Thilo Hotfiel and Prof. Jurgen Freiwald will delve into the benefits of heat therapy in the sports context, also exploring the different roles of heat and cold therapy. #AngeliniPharma #EveryStepCloser
Pagine affiliate
Pagine simili
Sfoglia le offerte di lavoro
Raccolta fondi
Ultimo round
Grant1.686.530,00 USD
Investitori
European Commission